For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Common Variants in Interleukin-1-Beta Gene Are Associated with Intracranial Hemorrhage and Susceptibility to Brain Arteriovenous MalformationKim H.a, b, h · Hysi P.G.a · Pawlikowska L.a, h · Poon A.g · Burchard E.G.b–d, h · Zaroff J.G.c, i · Sidney S.i · Ko N.U.e · Achrol A.S.a · Lawton M.T.f · McCulloch C.E.b · Kwok P.-Y.g, h · Young W.L.a, e, f
aCenter for Cerebrovascular Research, Department of Anesthesia and Perioperative Care, Departments of bEpidemiology and Biostatistics, cMedicine, dBiopharmaceutical Sciences, eNeurology and fNeurological Surgery, gCardiovascular Research Institute, and hInstitute for Human Genetics, University of California, San Francisco, Calif., and iDivision of Research, Kaiser Permanente Medical Care Program, Oakland, Calif., USA Corresponding Author
Helen Kim, PhD
UCSF, 1001 Potrero Avenue, Rm. 3C-38
San Francisco, CA 94110 (USA)
Tel. +1 415 206 8906, Fax +1 415 206 8907
Background: Polymorphisms in the proinflammatory cytokine interleukin (IL)-1β gene have been associated with systemic atherogenesis, thrombosis and rupture. The aim of this study was to investigate associations between single nucleotide polymorphisms (SNPs) in IL-1β and intracranial hemorrhage (ICH) in the natural course of brain arteriovenous malformation (BAVM) patients. Method: Two IL-1β promoter SNPs (–511C→T, –31T→C) and 1 synonymous coding SNP in exon 5 at +3953C→T (Phe) were genotyped in 410 BAVM patients. We performed a survival analysis of time to subsequent ICH, censoring cases at first treatment, death or last follow-up. A Cox regression analysis was performed to obtain hazard ratios (HRs) for genotypes adjusted for age, sex, Caucasian race/ethnicity and hemorrhagic presentation. Results: Subjects with the –31 CC genotype (HR = 2.7; 95% CI 1.1–6.6; p = 0.029) or the –511 TT genotype (HR = 2.6; 95% CI 1.1–6.5; p = 0.039) had a greater risk of subsequent ICH compared with reference genotypes, adjusting for covariates. The +3953C→T SNP was not significantly associated with an increased ICH risk (p = 0.22). The IL-1β promoter polymorphisms were also associated with BAVM susceptibility among a subset of 235 BAVM cases and 255 healthy controls of Caucasian race/ethnicity (p < 0.001). Conclusion: IL-1β promoter polymorphisms were associated with an increased risk of ICH in BAVM clinical course and with BAVM susceptibility. These results suggest that inflammatory pathways, including the IL-1β cytokine, may play an important role in ICH.
© 2008 S. Karger AG, Basel
Brain arteriovenous malformation (BAVM) is a rare but important cause of hemorrhagic stroke in young adults. Most cases are sporadic, but BAVM also frequently occurs in patients with hereditary hemorrhagic telangiectasia , an autosomal dominant disorder (OMIM No. 600376) involving loss-of-function mutations in transforming growth factor-β pathway genes. Although the etiology of BAVM is obscure, genetic susceptibility may play a role in both susceptibility and disease progression .
Proinflammatory cytokines, including interleukins (ILs), have been reported to be involved in brain ischemic injury; increased availability of ILs in the brain tends to exacerbate damage from ischemic insult [3,4,5]. The effect of IL-1β during the ischemic insult appears to increase, owing to the synergistic effect of other cytokines . Moreover, BAVM tissue specimens express 100- to 1,000-fold higher protein levels of inflammatory markers (myeloperoxidase, matrix metalloproteinase 9 and IL-6) compared with control brain tissue [7, 8].
Recently, common functional polymorphisms in the IL-1β gene have been associated with various cerebrovascular phenotypes, including ischemic stroke  and aneurysmal subarachnoid hemorrhage . Therefore, we hypothesized that IL-1β polymorphisms may influence the natural course of BAVM and the risk of subsequent intracranial hemorrhage (ICH) and/or disease susceptibility.
BAVM cases were recruited at the University of California, San Francisco (UCSF) or the Kaiser Permanente Medical Care Plan (KPMCP) of Northern California. Clinical presentation and morphological characteristics were recorded as described previously [11, 12], using standardized definitions . All subjects provided informed consent, and the studies were approved by the institutional review boards of the UCSF and the KPMCP.
Three polymorphic variants in IL-1β (–511C→T, –31T→C and +3953C→T) were selected on the basis of the putative functional effect and previous associations with related phenotypes (table 1) [9, 10]. Genotyping was performed using a template-directed dye-terminator incorporation assay with fluorescence polarization detection . Positive and negative controls were included on all plates to minimize genotyping errors, and any discrepancies were repeated.
Linkage disequilibrium, i.e. pairwise correlation, between single nucleotide polymorphisms (SNPs) was determined using both D′ and r2 measures . The χ2 goodness-of-fit test was used to assess whether genotypes were in Hardy-Weinberg equilibrium (HWE) within each and pooling across all race/ethnic groups.
We performed the Kaplan-Meier survival analysis and log-rank test of time to subsequent ICH (primary outcome), defined as a symptomatic event with signs of new intracranial blood on computed tomographic or magnetic resonance imaging, after initial presentation but prior to any intervening treatment. Patients were censored at either date of first treatment, last follow-up or death. Clinical presentation leading to diagnosis was coded dichotomously as hemorrhagic or nonhemorrhagic.
Univariate and multivariate Cox regression analysis was performed to obtain hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for age, sex, Caucasian race/ethnicity and initial hemorrhagic presentation. The HR describes the relative risk of ICH based on the comparison of ICH rates in the high-risk versus low-risk (reference) genotype groups.
We also conducted a secondary case-control analysis of 235 BAVM patients and 255 healthy controls of self-reported Caucasian ancestry. Controls were healthy volunteers from the same clinical catchment area without a significant past medical history recruited for a pharmacogenetics study conducted at the UCSF . Logistic regression analysis was performed to obtain odds ratios (ORs) and 95% CIs for each polymorphism, adjusting for age and sex.
As a sensitivity analysis, we conducted a random effects meta-analysis to validate our case-control findings using the pooled IL-1β –31 CC genotype frequency of Caucasian controls from 14 published studies [17,18,19,20,21,22,23,24,25,26,27,28,29,30]. A restricted maximum likelihood method was used to estimate the between-study variance as implemented in the Stata metareg package . All statistical analyses were conducted using Intercooled Stata version 9 (StataCorp LP, College Station, Tex., USA).
Demographic and clinical characteristics of the BAVM cohort are shown in table 2. A total of 27 ICH events occurred during a total of 1,296 person-years at risk, with a mean (standard deviation) follow-up of 3.1 (7.5) years. The mean age of BAVM patients was 35.6 (17.4) years, 55% were of self-reported Caucasian race/ethnicity, 52% were females, and 42% presented with hemorrhage.
Genotype frequencies of IL-1β polymorphisms were in HWE among BAVM patients within and across all race/ethnic categories (p > 0.05). The 2 promoter SNPs were strongly correlated and in almost perfect linkage disequilibrium (D′ = 0.98, r2 = 0.96), whereas the exon 5 SNP was more weakly correlated with the promoter SNPs (D′ = 0.74, r2 = 0.08).
Kaplan-Meier hemorrhage-free survival curves and corresponding log-rank tests by IL-1β genotypes are shown in figure 1, with numbers at risk shown at each 2-year time interval. Patients with the IL-1β –31 CC genotype (p = 0.008) or the –511 TT genotype (p = 0.013) had a greater rate of subsequent ICH compared with reference genotypes (fig. 1a, b). No significant difference in the rate of subsequent ICH was observed for the IL-1β +3953C→T polymorphism (p = 0.145; fig. 1c).
The univariate and multivariate HRs for IL-1β polymorphisms are summarized in table 3. Patients with the –31 CC genotype (HR = 2.7; 95% CI 1.1–6.6; p = 0.029) or the –511 TT genotype (HR = 2.6; 95% CI 1.1–6.5; p = 0.039) had a greater risk of subsequent ICH compared with reference genotypes, adjusting for covariates. A nonsignificant increased risk was observed in those with the +3953 CC genotype (HR = 2.2; 95% CI 0.6–7.7; p = 0.218).
Similar effect sizes for the IL-1β –31 CC genotype were observed when restricting analyses to Caucasians (HR = 2.4; 95% CI 0.7–8.3; p = 0.175) or after further adjustments for deep venous drainage and BAVM size (HR = 2.5; 95% CI 0.9–6.9; p = 0.078). However, these estimates were nonsignificant due to the reduced sample size from examining 1 race/ethnic group or missing angiographic data.
To determine if IL-1β SNPs were associated with disease susceptibility, we performed a case-control analysis restricted to Caucasians. IL-1β –31 CC or –511 TT genotypes were present at a much higher frequency in BAVM cases than in controls (table 4). The risk of BAVM was higher in subjects with the putative high-risk IL-1β genotypes after adjusting for age and sex: OR of 3.2 (95% CI 1.7–6.1; p < 0.001) for the –31 CC genotype and for the –511 TT genotype, respectively, and 1.8 (95% CI 1.2–2.7; p = 0.004) for the +3953 CC genotype (table 4).
However, the observed high-risk genotype frequencies for the 2 promoter SNPs in our Caucasian control population were lower than those previously reported in the published literature and were also out of HWE (p = 0.009). Therefore, we conducted a meta-analysis to validate our IL-1β –31T→C findings using the pooled genotype frequency of controls reported in 14 published studies conducted in Caucasians [17,18,19,20,21,22,23,24,25,26,27,28,29,30]. The IL-1β –31 CC genotype association remained when comparing the BAVM genotype frequency with the published controls. On average, the –31 CC genotype frequency was 5.1% higher in BAVM cases (17%) compared with pooled controls (12%), accounting for variation across studies (p = 0.042).
We provide the first report of an association between polymorphic variants in the IL-1β gene with both ICH risk in the natural course of BAVM patients and BAVM susceptibility. Several lines of evidence support our findings. First, all 3 SNPs have previously been implicated in various cerebrovascular phenotypes, including ischemic injury , stroke [9, 32] and aneurysmal rupture . For example, the TT genotype of the IL-1β –511C→T polymorphism was significantly associated with an increased risk of subarachnoid hemorrhage  and small vessel disease stroke  in a Polish population, but with a decreased risk of ischemic stroke in an Italian population . Second, animal studies have shown that IL-1β expression levels are significantly upregulated after intracerebral hemorrhage . Third, all 3 polymorphisms are located in known functional regions of the IL-1β gene (the promoter and an exon), and several studies have demonstrated a genotype-phenotype association. The T allele of the –511 promoter SNP is correlated with enhanced IL-1β production in vivo, and the –31 promoter SNP is located in a TATA box transcription initiation site . The +3953C→T (Phe) variant has been shown to influence in vitro IL-1β production in some [35, 36] but not in all studies . Haplotypes containing both –511T and –31C alleles have been shown to have increased transcriptional activity in vitro . Thus, the increased ICH risk in IL-1β high-risk genotype carriers may be due to increased local or peripheral inflammation influencing AVM disease progression.
The IL-1β gene located on chromosome 2q14 is approximately 7 kb long with 7 exons. However, it sits in an IL-1 cytokine cluster spanning approximately 430 kb, containing genes for IL-1α, IL-1β and IL-1 receptor antagonist. Therefore, the association we observed with IL-1β variants could possibly be due to linkage disequilibrium (LD) with variants in these related IL-1 genes or additional variants in the IL-1β gene. As expected, analyses of both IL-1β promoter SNPs yielded similar findings due to the strong LD. Thus, we cannot distinguish whether 1 of the 2 promoter SNPs, or another SNP in the same LD block, is responsible for the observed associations with BAVM susceptibility and ICH.
An increasing number of reports suggest a role of inflammatory signaling in BAVM pathogenesis. Activin-like kinase 1, a transforming growth factor-β superfamily member, is mutated in hereditary hemorrhagic telangiectasia; a common activin-like kinase 1 polymorphism is also strongly associated with sporadic BAVM [39, 40]. The GG genotype of the IL-6 174G→C promoter polymorphism was associated with clinical presentation of ICH in BAVM patients  and with highest IL-6 expression levels in BAVM tissue ; IL-6 levels correlated strongly with IL-1β mRNA levels . Compared with control brain (structurally normal cortex removed during temporal lobectomy), BAVM tissue had an order of magnitude higher expression of the leukocyte marker myeloperoxidase, which highly correlated and colocalized with matrix metalloprotease 9 and IL-6 expression . Finally, a promoter polymorphism in the tumor necrosis factor-α (–238G→A) gene was associated with new hemorrhage in the natural course of a sample of 280 BAVM cases; the presence of the A allele increases the risk of ICH .
Together, these results suggest that inflammatory mechanisms are involved in BAVM susceptibility and progression and warrant replication and further investigation into the precise mechanism of how proinflammatory pathways are involved. A better understanding of BAVM pathogenesis is needed to prevent ICH and potentially help develop novel therapeutics for patient management.
The authors thank the UCSF-KPMCP BAVM Study Project members and patients for their participation, and Dr. Kathleen Giacomini for sharing control DNA (U01 GM061390). This work was supported by NIH grants: R01 NS34949, R01 NS41877 and P01NS44155 to W.L.Y. H.K. was supported in part by K23NS058357 and NIH/NCRR UCSF-CTSI grant number UL1 RR024131. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Helen Kim, PhD
UCSF, 1001 Potrero Avenue, Rm. 3C-38
San Francisco, CA 94110 (USA)
Tel. +1 415 206 8906, Fax +1 415 206 8907
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.